Abstract:Background/Introduction In patients with cardiogenic shock (CS), a combination of Impella-a percutaneous ventricular assist device with a catheter-type micro-axial heart pump-and venoarterial extracorporeal membrane oxygenation (ECPELLA) has been reported to have a better prognosis compared to venoarterial extracorporeal membrane oxygenation (VA-ECMO) alone, although it was associated with more complications. In contemporary clinical practice, ECPELLA has often been used in place of VA-ECMO alone. However, in many cases of acute myocardial infarction (AMI) with CS, there is controversy regarding the prioritization of Impella or VA-ECMO installation. Purpose The current study aims to clarify the factors of Impella use before VA-ECMO, the impact of the timing of Impella insertion (before or after VA-ECMO) for 30-day mortality, and major adverse events (MAEs) in the two groups. Methods The Japanese registry for Percutaneous Ventricular Assist Device (J-PVAD) Registry is a nationwide registry enrolling 5,718 consecutive Japanese patients treated with Impella between February 2020 and December 2022. The current study population consisted of 1,082 patients with AMI complicated by CS excluding cardiopulmonary arrest on arrival or using only Impella, who were divided into 2 groups; Impella use before and after VA-ECMO. Results Among the current study population, 323 patients (30%) used Impella before VA-ECMO, and 759 patients (70%) used Impella after VA-ECMO. Patients who used Impella before VA-ECMO were older (72 vs. 68 years old, P<0.0001) and had higher left ventricular ejection fraction (LVEF) (30 vs 20 %, P<0.0001), lower lactate level (5.6 vs 9.1 mmol/L, P<0.0001), and more often ST-elevation myocardial infarction (MI) (82% vs 76%, P<0.0001), whereas those patients had less often out-of-hospital cardiac arrest (OHCA) (13% vs 45%, P<0.0001), in-hospital cardiac arrest (IHCA) (27% vs 63%, P<0.0001), and prior heart failure (9.5% vs 16%, P=0.006). The factors of Impella use before VA-ECMO were 75 years or older, dyslipidemia, the absence of OHCA, the absence of IHCA, the absence of prior MI, and the absence of LVEF less than 30%. The cumulative 30-day incidence of all-cause death was 46.2% in patients with Impella use before VA-ECMO and 53.4% in those with Impella use after VA-ECMO (Log-rank P=0.02). After adjusting confounders, there was no excess risk of Impella use before VA-ECMO relative to Impella use after VA-ECMO (adjusted HR, 0.87; 95%CI, 0.55-1.37; P=0.55). Regarding major adverse events, hemolysis was significantly more frequent in patients with Impella use before VA-ECMO, while stroke was significantly more common in patients with Impella use after VA-ECMO. Conclusions The prognosis with AMI complicated by CS requiring ECPELLA remained poor. The 30-day mortality was lower in patients with Impella use before VA-ECMO compared to after VA-ECMO. However, after adjusting for confounders, there was no difference between the two groups.

Prevalence of bleeding events in real-world Japanese registry for Percutaneous Ventricular Assist Device

Prognostic Survey of ECPELLA in Japanese Patients With Acute Myocardial Infarction and Cardiogenic Shock - Findings From the Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD)

Current Use and Impact of Pulmonary Artery Catheters on the Short-Term Outcomes in Patients With Cardiogenic Shock Treated With an Impella: Findings From the Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD)

Safety and efficacy of surgical revascularization with percutaneous ventricular assist device for acute myocardial infarction complicated by cardiogenic shock: Japanese national registry study

Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD)

Predicting survival after Impella implantation in patients with cardiogenic shock: The J‐PVAD risk score

Trends in Mechanical Circulatory Support Use and Outcomes of Patients With Cardiogenic Shock in Japan, 2010 to 2020 (from a Nationwide Inpatient Database Study)

In-Hospital Mortality in Patients With Cardiogenic Shock Requiring Veno-Arterial Extracorporeal Membrane Oxygenation With Concomitant Use of Impella vs. Intra-Aortic Balloon Pump - A Retrospective Cohort Study Using a Japanese Claims-Based Database

Efficacy and safety of catheter ablation for idiopathic premature ventricular contraction in Japan: from the nationwide Japan Catheter Ablation Registry

Impact of off-hours admissions in STEMI-related cardiogenic shock managed with microaxial flow pump - insights from J-PVAD

Influence of polyvascular disease on clinical outcome in patients undergoing transcatheter aortic valve implantation via transfemoral access

Influence of timing of impella insertion on the prognosis of acute myocardial infarction complicated with cardiogenic shock requiring ECPELLA

Safety and Feasibility of a Novel Total Percutaneous Post-Closure Technique After Bedside Impella Decannulation in Patients With Cardiogenic Shock

Clinical Outcomes of Left Ventricular Assist Device Bleeding Complication

Occurrence and incidence rate of peripheral intravascular catheter-related phlebitis and complications in critically ill patients: a prospective cohort study (AMOR-VENUS study)

Contemporary optimal therapeutic strategy with escalation/de-escalation of temporary mechanical circulatory support in patients with cardiogenic shock and advanced heart failure in Japan

The association between introduction of the micro-axial flow pump Impella in hospitals and in-hospital mortality in patients treated with extracorporeal membrane oxygenation: interrupted time-series analyses

Impacts of Hospital Volume and Patient-Hospital Distances on Outcomes of Older Adults Receiving Percutaneous Microaxial Ventricular Assist Devices for Cardiogenic Shock

Clinical characteristics and short-term outcomes of patients with critical acute pulmonary embolism requiring extracorporeal membrane oxygenation: from the COMMAND VTE Registry-2

Percutaneous Microaxial Ventricular Assist Device Versus Intra-Aortic Balloon Pump for Nonacute Myocardial Infarction Cardiogenic Shock

Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An IMACS registry analysis